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Translating GWAS‑identified loci 
for cardiac rhythm and rate using 
an in vivo image‑ and CRISPR/
Cas9‑based approach
Benedikt von der Heyde 1,2,14, Anastasia Emmanouilidou1,2,14, Eugenia Mazzaferro1,2, 
Silvia Vicenzi1,2, Ida Höijer1,2, Tiffany Klingström2,3, Sitaf Jumaa1,2, Olga Dethlefsen4,5, 
Harold Snieder 6, Eco de Geus 7, Adam Ameur 1,2,8, Erik Ingelsson 2,9,10,11, 
Amin Allalou2,12, Hannah L. Brooke13 & Marcel den Hoed 1,2*
A meta‑analysis of genome‑wide association studies (GWAS) identified eight loci that are associated 
with heart rate variability (HRV), but candidate genes in these loci remain uncharacterized. We 
developed an image‑ and CRISPR/Cas9‑based pipeline to systematically characterize candidate genes 
for HRV in live zebrafish embryos. Nine zebrafish orthologues of six human candidate genes were 
targeted simultaneously in eggs from fish that transgenically express GFP on smooth muscle cells 
(Tg[acta2:GFP]), to visualize the beating heart. An automated analysis of repeated 30 s recordings 
of beating atria in 381 live, intact zebrafish embryos at 2 and 5 days post‑fertilization highlighted 
genes that influence HRV (hcn4 and si:dkey-65j6.2 [KIAA1755]); heart rate (rgs6 and hcn4); and the 
risk of sinoatrial pauses and arrests (hcn4). Exposure to 10 or 25 µM ivabradine—an open channel 
blocker of HCNs—for 24 h resulted in a dose‑dependent higher HRV and lower heart rate at 5 days 
post‑fertilization. Hence, our screen confirmed the role of established genes for heart rate and rhythm 
(RGS6 and HCN4); showed that ivabradine reduces heart rate and increases HRV in zebrafish embryos, 
as it does in humans; and highlighted a novel gene that plays a role in HRV (KIAA1755).
Heart rate variability (HRV) reflects the inter-beat variation of the RR interval. HRV is controlled by the sinoatrial 
node, which receives input from the autonomic nervous system. Autonomic imbalance has been associated with 
work stress and other modifiable or non-modifiable risk  factors1, and is reflected in lower HRV. Lower HRV has 
been associated with higher cardiac morbidity and  mortality2, as well as with a higher risk of all-cause  mortality3. 
HRV can be quantified non-invasively using an ECG, making HRV a useful clinical marker for perturbations of 
the autonomic nervous system. However, the mechanisms influencing HRV remain poorly understood.
Recently, we and others identified the first loci that are robustly associated with HRV, using a meta-analysis 
of genome-wide association studies (GWAS) with data from 53,174  participants3. Five of the identified loci had 
open
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previously been associated with resting heart  rate4. The heart rate associated loci in turn are associated with 
altered cardiac conduction and risk of sick sinus  syndrome5. In silico functional annotation of the five loci that 
are associated with both  HRV3 and heart  rate4 resulted in the prioritization of six candidate  genes3. Functional 
follow-up experiments—ideally in vivo—are required to conclude if these genes are indeed causal, and examine 
if they influence HRV, heart rate, and/or cardiac conduction.
Mouse models are commonly used in cardiac research, but adult mice show substantial differences in cardiac 
rate and electrophysiology when compared with  humans5. Inherently, these differences complicate extrapolation 
of results from mouse models to  humans5. Additionally, rodents are not suitable for high-throughput, in vivo 
characterization of cardiac rhythm and rate. Such screens are essential to systematically characterize positional 
candidate genes in the large number of loci that have now been identified in GWAS for  HRV3, heart  rate6 and 
cardiac  conduction7,8. Hence, novel model systems that facilitate systematic, in vivo characterization of a large 
number of candidate genes are needed.
In recent years, the zebrafish has become an important model system for genetic and drug screens for human 
 diseases9,10. Despite morphological differences to the human heart, zebrafish have a functional, beating heart 
at ~ 24 h post-fertilization, and the ECG of the two-chambered adult zebrafish heart is similar to that of  humans11. 
Conditions affecting cardiac electrophysiology have previously been successfully modeled in zebrafish. For exam-
ple, nkx2.5 is necessary for normal  HRV12, mutations in kcnh2 have been used to model long QT  syndrome13, 
trpm7 was shown to influence heart rate and risk for sinoatrial  pauses14, and knockdown of hcn4 has been used 
to model human sick sinus syndrome in  zebrafish15. Fluorescently labeled transgenes facilitate visualization 
of cell types and tissues of interest, which can now be accomplished in high throughput thanks to advances 
in automated positioning of non-embedded, live zebrafish  embryos16–18. In addition, the zebrafish has a well-
annotated genome, with orthologues of at least 71.4% of human  genes19. These genes can be targeted efficiently 
and in a multiplexed manner using Clustered, Regulatory Interspaced, Short Palindromic Repeats (CRISPR) and 
CRISPR-associated systems (Cas)20. All characteristics combined make zebrafish embryos an attractive model 
system to systematically characterize candidate genes for cardiac rhythm, rate and conduction.
The aim of this study was to objectively characterize the most promising candidate genes in loci associated 
with both HRV and heart rate for a role in cardiac rhythm, rate and function, using a large-scale, image-based 
screen in zebrafish embryos.
Results
Experimental pipeline. Our experimental pipeline is outlined in Fig.  1 and Supplementary Fig S1. 
CRISPR/Cas9 founders  (F0) were generated in which all nine zebrafish orthologues of six human candidate 
genes were targeted simultaneously using a multiplexed approach (Table 1)20. We used a background with trans-
genically expressed, fluorescently labelled smooth muscle cells (Tg[acta2:GFP])21, to visualize the beating heart. 
Founders were raised to adulthood and in-crossed. On the morning of day 2 post fertilization (dpf),  F1 embryos 
were individually anesthetized, to minimize exposure to tricaine and to standardize the imaging procedure. We 
then captured bright field images of whole embryos in 12 orientations to quantify body size, and recorded the 
beating atrium for 30 s in 383 live, intact embryos, at 152 frames/s using an automated positioning system, fluo-
rescence microscope and CCD camera (see “Methods” section). After image acquisition, embryos were washed, 
dispensed in 96-well plates, and placed in an incubator at 28.5 °C, until 5dpf. Of the 383 embryos imaged at 2dpf, 
326 were imaged again on the morning of day 5 (Supplementary Fig. S2). Importantly, only three embryos died 
between 2 and 5dpf. This repeated measures design allowed us to quantify genetic effects on cardiac outcomes 
and body size at two key stages of early  development22. A custom-written MatLab script was used to automati-
cally quantify HRV and heart rate from the recordings acquired at 2 and 5dpf (see “Methods” section). After 
imaging at 5dpf, embryos were sacrificed and sequenced at the CRISPR/Cas9-targeted sites, followed by align-
ment; quality control; variant calling; variant annotation; and statistical analysis. 
Descriptive results. At 2dpf, some embryos showed sinoatrial pauses (n = 39, 10.3%, Supplementary 
Recording S1, Fig. 2) and arrests (n = 36, 9.5%, Supplementary Recording S1, Fig. 2); cardiac edema (n = 16, 
4.2%); or uncontrolled atrial contractions (n = 1, 0.2%, Supplementary Recording S2, Fig.  2). At 5dpf, fewer 
embryos displayed sinoatrial pauses (n = 9, 2.7%, only one of which also showed a sinoatrial pause at 2dpf); 
sinoatrial arrests (n = 3, 0.9%, none of which showed a sinoatrial arrest at 2dpf); and cardiac edema (n = 15, 4.5%, 
nine of which already had cardiac edema at 2dpf); while uncontrolled atrial contractions and an abnormal car-
diac morphology (Supplementary Recording S3, Fig. 2) were first observed in some embryos at 5dpf (n = 9, 2.7% 
and n = 6, 1.8%, especially). For embryos free from cardiac abnormalities, distributions of HRV and heart rate at 
2 and 5dpf are shown in Supplementary Fig. S3. Distributions for body size are shown in Supplementary Fig. S4.
After imaging at 5dpf, all 383 embryos were sequenced at the nine CRISPR/Cas9 targeted sites (Table 1, 
Supplementary Fig. S5). Transcript-specific dosages were calculated by weighing the number of mutated alleles 
by the mutations’ predicted impact on protein function, based on Ensembl’s variant effect predictor (VEP). A 
total of 123 unique alleles were identified across the nine CRISPR/Cas9-targeted sites (Supplementary Fig. S5), 
in which 169 unique mutations were called (Supplementary Table S3), ranging from three unique mutations 
in hcn4l to 34 in si:dkey-65j6.2 (one of two KIAA1755 orthologues). Frameshift inducing mutations were most 
common (47.9%), followed by missense variants (25.4%), in-frame deletions (14.2%), and synonymous variants 
(5.9%). Eighty-seven, seventy-two and ten mutations were predicted to have a high, moderate, and low impact 
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Figure 1.  Overview of the experimental pipeline showing the image-based acquisition and post-processing of 
images and samples. dpf days post-fertilization.
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on protein function, respectively (Supplementary Table S3). Two embryos with missed calls in more than two 
targeted sites were excluded from the analysis. In the remaining 381 embryos, sequencing call rate was > 98% 
for all but one targeted site, and missed calls were imputed to the mean. Seventy-eight embryos had a missed 
call for neo1b (Supplementary Table S4). Since these 78 embryos showed a similar distribution for all outcomes 
compared with the remaining embryos (not shown), and since the mutant allele frequency of neo1b was 93.4% 
for the successfully sequenced embryos, missing neo1b calls were also imputed to the mean.
We observed a normal distribution of the number of mutated alleles across the nine targeted orthologues 
(range 2–14 mutated alleles, Supplementary Fig. S6). Mutant allele frequencies—based on previously unreported 
variants located within ± 30 bp of the CRISPR/Cas9 cut sites—ranged from 4.1% for hcn4l to 93.4% for neo1b 
(Supplementary Table S4). We did not identify any mutations at three predicted off-target sites in the 381 suc-
cessfully sequenced embryos (Supplementary Table S2).
Effects of mutations in candidate genes on sinoatrial pauses and arrests. At 2dpf, each addi-
tional CRISPR/Cas9 mutated allele in the first exon of hcn4 resulted in a > 2.5-fold higher odds of sinoatrial 
pauses or arrests (Table 2, Supplementary Tables S5, S6). Embryos showing pauses or arrests during positioning 
and orienting in the microscope’s field of view, but not during image acquisition were not included in the statis-
tical analysis. Still, it is worth noting that pauses were observed during positioning in four of the nine embryos 
that later turned out to be compound heterozygous for CRISPR/Cas9-induced nonsense mutations in hcn4; and 
in four of the eight embryos carrying a mutated allele in hcn4 as well as in hcn4l. Importantly, zebrafish embryos 
can survive without a functionally beating heart at this stage of development, thanks to adequate tissue oxygena-
tion by  diffusion23. This allowed us to observe genetically driven sinoatrial arrests that would have been lethal in 
embryos of most other species.
Of the 39 embryos with a sinoatrial pause during the acquisition at 2dpf; two embryos died before imaging 
at 5dpf, and only one also showed a pause or arrest at 5dpf. Since only six new pauses were observed at 5dpf, 
the statistical power to detect genetic effects on sinoatrial pauses was low at 5dpf. Earlier we performed a pilot 
experiment in 406 2dpf offspring of an in-cross of heterozygous carriers of the sa11188  mutation24, a nonsense 
mutation in exon 2 of hcn4. Of these 406 embryos, 95, 206 and 105 carried nonsense mutations in 0, 1 and 2 
hcn4 alleles at 2dpf, respectively. Of the 406 embryos, 349 passed quality control at 5dpf, or which 81, 177 and 
91 embryos carried 0, 1 and 2 mutated alleles, respectively. The statistical power to detect effects of nonsense 
mutations in hcn4 on sinoatrial pauses was thus substantially higher in the pilot study. Combining data from 
the CRISPR/Cas9 and sa11188 experiments provided us with 51 and 43 sinoatrial pauses at 2 and 5dpf, and 
confirmed an > twofold higher odds of sinoatrial pauses for each additional mutated hcn4 allele at 2 and at 5dpf 
(Table 2). Embryos carrying nonsense mutations in both hcn4 alleles even had ninefold higher odds of sinoatrial 
pauses at 5dpf than embryos free from CRISPR/Cas9-induced and sa11188 mutations in hcn4 (P = 1.4 × 10–5, 
Table 2). Genotype distributions did not deviate from Hardy Weinberg equilibrium in either the CRISPR/Cas9 
or sa11188 experiment, confirming that nonsense mutations in hcn4 were not lethal between 2 and 5dpf.
Of the remaining candidate genes examined in the multiplexed CRISPR/Cas9 experiment, only mutations 
in syt10 showed a trend for higher odds of sinoatrial pauses at 2dpf (Supplementary Table S6). This is likely a 
transient effect, since the six embryos with nonsense mutations in both syt10 alleles that showed a sinoatrial 
pause at 2dpf did not die between 2 and 5dpf and did not show a sinoatrial pause at 5dpf. In fact, each additional 
mutated allele in syt10 tended to protect from sinoatrial pauses at 5dpf; none of the 41 embryos with nonsense 
mutations in both syt10 alleles showed a sinoatrial pause at 5dpf (Supplementary Table S5).
Effects of mutations in candidate genes on heart rate variability and heart rate. We next exam-
ined the effect of CRISPR/Cas9-induced mutations on HRV and heart rate in embryos free from sinoatrial 
pauses and arrests. Embryos with CRISPR/Cas9-induced mutations in hcn4 tended to have a higher HRV and a 
Table 1.  Selected candidate genes and their zebrafish orthologues in GWAS-identified heart rate variability-
associated loci. *rsID refers to the lead SNP(s) of the GWAS-identified  loci3.
rsID* Chr Human gene ENSG stable ID Zebrafish orthologue ENSDARG stable ID
rs4262









14 RGS6 ENSG00000182732 rgs6 ENSDARG00000015627
rs2680344 15 HCN4 ENSG00000138622
hcn4 ENSDARG00000061685
hcn4l ENSDARG00000074419
rs1812835 15 NEO1 ENSG00000067141
neo1a ENSDARG00000102855
neo1b ENSDARG00000075100
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higher heart rate at 2dpf (Fig. 3, Supplementary Fig. S3, Supplementary Tables S7, S8). From 2 to 5dpf, embryos 
with CRISPR/Cas9-induced mutations in hcn4 on average had a larger decrease in HRV and a larger increase 
in heart rate, resulting in a lower HRV and a higher heart rate at 5dpf (Figs. 3, 4, 5, Supplementary Fig. S3, Sup-
plementary Tables S7, S8). At 5dpf, standardized effect sizes of mutations in hcn4 on HRV and heart rate were of 
similar magnitude but opposite direction (Fig. 5, Supplementary Tables S7, S8). For heart rate, effect estimates 
were directionally consistent across the CRISPR/Cas9 and sa11188 experiments, but were more conservative in 
the latter, both at 2 and at 5dpf (Fig. 5). A lower frame rate in the sa11188 experiment (i.e. 20 frames/s) meant we 







N/A Abnormal cardiac morphology /
reduced contractility
Figure 2.  Visualization of cardiac rhythmic or other abnormalities, highlighted by arrows. Sinoatrial pauses 
were defined as the atrium ceasing to contract for > 3 × the median inter beat interval of the embryo. A sinoatrial 
arrest was defined as an event where the atrium stopped contracting for > 2 s. Abnormal cardiac morphology 
was defined as the atrium appearing as a tube-like structure, and impaired cardiac contractility was defined as 
the atrium vibrating rather than contracting.
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Across the remaining candidate genes, the 17 embryos with one CRISPR/Cas9 mutated rgs6 allele on aver-
age had a nearly 0.5 SD units lower heart rate. The effect size for HRV was ~ twofold lower and did not reach 
significance (Fig. 3, Supplementary Fig. S3, Supplementary Tables S4, S7). Furthermore, embryos with mutations 
in si:dkey-65j6.2 (i.e. KIAA1755) tended to have: (1) a higher HRV at 2dpf; (2) a larger decrease in HRV from 
2 to 5dpf; and (3) a higher HRV at 5dpf (Fig. 3, Supplementary Fig. S3, Supplementary Table S7). While we did 
not observe an effect of mutations in si:dkey-65j6.2 or quo on heart rate at 2 or 5dpf, embryos with mutations in 
si:dkey-65j6.2 tended to have a smaller increase in heart rate from 2 to 5dpf. An opposite trend was observed in 
embryos with mutations in quo (Fig. 3, Supplementary Table S7). Similarly, embryos with nonsense mutations 
in both neo1a alleles showed a larger increase in heart rate from 2 to 5dpf than embryos free from CRISPR/
Cas9-induced mutations, without showing a difference in heart rate at 2 or 5dpf (Fig. 3, Supplementary Table S8). 
This suggests that 5dpf may have been too early to detect true genetic effects of mutations in KIAA1755 and/or 
NEO1 orthologues on heart rate.
Effect of mutations in candidate genes on body size. Besides having a lower heart rate at 2dpf, 
embryos with CRISPR/Cas9-induced mutations in rgs6 were shorter at 2 and 5 dpf, and had a smaller dorsal 
body surface area normalized for body length at 5dpf (Supplementary Figs. S4, S7, Supplementary Table S9). 
Embryos with mutations in si:dkey-65j6.2 tended to be leaner at both 2 and 5dpf, while embryos with mutations 
in quo were larger at both time points (Supplementary Figs. S4, S7, Supplementary Tables S9, S10). Embryos 
with mutations in neo1a tended to be larger at 2dpf but not at 5dpf (Supplementary Figs. S4, S7, Supplementary 
Tables S9, S10).
Transcriptomic analyses. Mutagenesis by targeting a proximal site in the protein-coding sequence using 
CRISPR/Cas9 has been shown to trigger a compensatory upregulation of the expression of transcripts with 
sequence  similarity25. To explore if such compensation may have influenced our results, we next targeted hcn4 
and/or hcn4l using CRISPR/Cas9 at the single cell stage, pooled five embryos per sample at 5dpf, and performed 
a qRT-PCR analysis to examine compensatory effects on transcripts with at least 75% sequence similarity to the 
main zebrafish hcn4 transcript (Supplementary Tables S11, S12). Compared with control-injected embryos, tar-
geting hcn4 or hcn4 and hcn4l simultaneously—using the same gRNAs and protocols used to generate CRISPR/
Cas9 founders—resulted in a lower expression of hcn4 at the CRISPR/Cas9-targeted site at 5dpf, confirming on-
target activity for the hcn4 gRNA (Fig. 6). We observed no effect of targeting hcn4 on expression of the last exon 
of hcn4, which may reflect the low proportion of embryos with a nonsense mutation in both hcn4 alleles in the 
phenotypic screen (i.e. 2.4%, Supplementary Table S4). However, we did observe what may be a compensatory 
increase in the expression of zebrafish orthologues of HCN1 and HCN2 in samples of hcn4-targeted embryos 
(Fig. 6). While the effect of targeting hcn4 on the expression of CABZ01086574.1 (likely an orthologue of HCN2) 
and the trend for an effect on hcn1 expression were driven by one sample of hcn4-targeted embryos, the com-
Table 2.  Effect of mutations in hcn4 on sinoatrial pauses in data from the CRISPR/Cas9  F1 and sa11188 
experiments combined. Associations between the presence of sinoatrial pauses during the 30 s recording and 
the number of mutated alleles in hcn4 weighted by the predicted effect of those mutations on protein function 
(additive); or in embryos with nonsense mutations in both hcn4 alleles vs. embryos free from CRISPR/Cas9-
induced or sa11188 mutations in hcn4 (2 vs. 0) at 2 days post-fertilization (dpf), 5dpf, or at either time point 
(any). In the CRISPR/Cas9 experiment, associations were examined using logistic regression, adjusting for 
time of day, batch and for the weighted number of mutated alleles in the other genes as fixed factors; in the 
sa11188 experiment and combined analysis, associations were examined using mixed models (xtmelogit in 
Stata), with embryos nested in batches and experiments and adjusting for time of day as a fixed factor. At 
2dpf, 26 and 94 unaffected larvae were dropped from the additive and ‘2 vs. 0’ analyses in the CRISPR/Cas9 
F1 larvae due to multicollinearity. These observations were included in the combined analysis.
Age Model Study nunaffected naffected OR LCI UCI P
2dpf
Additive CRISPR/Cas9  F1 258 39 2.749 1.461 5.171 1.7 × 10–3
sa11188 394 12 1.697 0.695 4.148 2.5 × 10–1
Combined 678 51 2.245 1.358 3.710 1.6 × 10–3
2 vs. 0 CRISPR/Cas9  F1 127 23 3.667 0.633 21.249 1.5 × 10–1
sa11188 193 7 2.529 0.468 13.657 2.8 × 10–1
Combined 414 30 2.916 0.851 9.993 8.9 × 10–2
5dpf
Additive CRISPR/Cas9  F1 312 9 2.460 0.680 8.899 1.7 × 10–1
sa11188 308 34 2.252 1.303 3.893 3.7 × 10–3
Combined 620 43 2.762 1.320 5.782 7.0 × 10–3
2 vs. 0 CRISPR/Cas9  F1 231 4 – – – –
sa11188 151 16 7.885 1.719 36.163 7.9 × 10–3
Combined 382 20 9.015 3.348 24.277 1.4 × 10–5
Any
Additive Combined 631 90 2.121 1.456 3.090 8.9 × 10–5
2 vs. 0 Combined 391 47 3.687 1.651 8.232 1.5 × 10–3
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pensatory effect on hcn2b expression was more robust (Supplementary Table S13). Possible compensatory effects 
were observed when targeting hcn4, but not when targeting hcn4 and hcn4l simultaneously.
Nanopore off‑target sequencing. We next used in vitro Nanopore off-target sequencing (Nano-OTS)26 
in DNA from an adult Tg(acta2:GFP) positive fish used to generate CRISPR/Cas9 founders to explore if off-
target mutagenic activity may have influenced the results for hcn4; and if it may have played a role in the rela-
tively large number of missed sequencing calls for neo1b (Supplementary Table S4). No off-target mutations were 
identified for the hcn4 and neo1b gRNAs. In spite of five mismatches, we did observe one off-target mutation for 
the hcn4l gRNA, inside the coding region of the glutamine transporter slc38a3a (Supplementary Fig. S8). This 
off-target is unlikely to have influenced our results, since we did not observe effects of CRISPR/Cas9-induced 
mutations in hcn4l, and since the off-target mutagenic activity was even lower than the on-target activity for 
this gRNA (Supplementary Fig. S8). Furthermore, in vitro off-target activity does not necessarily imply in vivo 
mutagenic activity.
One off-target—in spite of four mismatches—was observed for the neo1a gRNA. Since this off-target was 
also characterized by low mutagenic activity and was located > 30 kb away from the nearest gene (Supplementary 
Fig. S8), large indel mutations at the neo1b target site due to neo1a or neo1b gRNA off-target activity are highly 
unlikely. Hence, it seems safe to conclude that either the 78 missing sequencing calls for neo1b were missing at 
random—e.g. due to inherently present variants interfering with primer binding—or that they were caused by 
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Figure 3.  Effect of CRISPR/Cas9-induced mutations in candidate genes on (change in) heart rate variability 
(top) and heart rate (bottom) at 2 days post-fertilization (dpf, n = 234) and 5dpf (n = 285). Full dots and solid 
whiskers show the effect size and 95% confidence interval (CI) for each additional mutated allele, weighted by 
the mutation’s predicted effect on protein function. Open dots and dotted whiskers indicate the effect and 95% 
CI for nonsense mutations in both alleles vs. no CRISPR/Cas9-induced mutations. Effects were adjusted for the 
weighted number of mutated alleles in the other targeted genes, as well as for time of day (fixed factors), with 
embryos nested in batches (random factor). quo and si:dkey-65j6.2 are orthologues of the human KIAA1755.
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Potential druggability. Three of the six human candidate genes taken forward for experimental follow-up 
showed evidence for a role in cardiac rhythm and/or rate in zebrafish embryos (i.e. HCN4, RGS6, KIAA1755). 
Only a trend for an effect on sinoatrial pauses was observed for the SYT10 orthologue, albeit with an opposite 
direction of effect at 2 and 5dpf. We next examined whether these four genes are already targeted by existing, 
FDA-approved medication using the drug-gene interaction (DGI) database (www.dgidb .org). Only HCN4 is 
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Figure 4.  Association of heart rate variability and heart rate at 2- and 5-days post-fertilization (dpf) and effect 
of nonsense mutations in both hcn4 alleles. Top: the association of heart rate variability and heart rate at 2 and 
5dpf, with embryos carrying nonsense mutations in both hcn4 alleles shown as pink diamonds. Bottom: the 
mean ± standard deviation of heart rate variability and heart rate at 2dpf and 5dpf for embryos with nonsense 
mutations in both hcn4 alleles (n = 5) vs. embryos without CRISPR/Cas9-induced mutations in hcn4 (n = 147).
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fied predicted interaction partners of the proteins encoded by the four genes, using  GeneMania29 and  STRING30. 
Some partners are targeted by FDA-approved medication (Supplementary Table S14), amongst which are several 
anti-hypertensive agents (e.g. Hydrochlorothiazide and Diazoxide), as well as a neuromuscular blocking agent 
(i.e. Botulinum toxin type A) and statins.
Ivabradine. Given the role of mutations in hcn4 on HRV and heart rate, we next examined the effect of 
24  h of exposure to 0, 10 or 25  µM ivabradine in DMSO on these outcomes at 5dpf, in embryos free from 
CRISPR/Cas9-induced mutations. One embryo with a sinoatrial pause was excluded from the analysis, as were 
13 embryos with suboptimal image or image quantification quality. In the remaining 118 embryos, ivabradine 
treatment resulted in a dose dependent higher HRV and lower heart rate, i.e. directionally opposite to the effects 
of mutations in hcn4 (Fig. 5, Supplementary Fig. S9, Supplementary Table S15). In fact, the effect on heart rate 
was of similar size—but opposite direction—for 10 µM ivabradine when compared with nonsense mutations 
in both hcn4 alleles, in data from the CRISPR/Cas9 and sa11188 experiments combined (Fig. 5). Interestingly, 
the effect of ivabradine on heart rate was 1.5 to 1.6-fold higher than its effect on HRV (Fig. 5, Supplementary 
Table S15).
Discussion
Large-scale, in vivo follow-up studies of candidate genes in GWAS-identified loci remain sparse. Here we present 
an objective, image-based pipeline to systematically characterize candidate genes for cardiac rhythm, rate, and 
conduction-related disorders. Using a zebrafish model system, we confirmed a role for genes previously impli-
cated in heart rate and rhythm (rgs6 and hcn4); show that effects of ivabradine on heart rate and rhythm are 
opposite when compared with the early-stage effects of mutations in one of the drug’s molecular targets (hcn4); 
identified a previously unanticipated gene influencing heart rate variability (si:dkey-65j6.2, i.e. KIAA1755); and 
observed effects of previously unanticipated genes on early growth and development (rgs6, quo, si:dkey-65j6.2, 
neo1a). In addition, we confirmed that mutations in hcn4 increase the odds of sinoatrial pauses and  arrests15. 
The latter adds weight to the notion that GWAS-identified common variants for complex traits can flag genes 
for which rare, detrimental mutations cause severe, early-onset  disorders7,31,32. We show here that an image- and 
CRISPR/Cas9-based zebrafish model system can be used for systematic characterization of candidate genes in 
GWAS-identified loci for complex traits. In the near future, integration of evidence across a range of species 
and approaches should close the existing gap between association and functional understanding. This will no 
doubt yield new targets that can be translated into efficient new medication for prevention and treatment of 
complex diseases.
The locus harboring HCN4 has been identified in GWAS for  HRV3, heart  rate4 and atrial  fibrillation33. HCN4 
belongs to the family of  If or “funny” channels, aptly named for being activated upon hyperpolarization and a 
non-selective permeability for  Na+ and  K+. It is expressed in the sinoatrial  node34,35 and plays an important role 
in cardiac pace  making36. The heart rate lowering agent  ivabradine37 is an open channel blocker of  If channels, 
and has been shown to reduce heart rate and increase HRV in  humans38,39. It also reduces cardiovascular and 
all-cause mortality in heart failure  patients40. In line with findings in humans, one day of treatment with ivabra-
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Figure 5.  The effect of mutations in hcn4 and treatment with ivabradine on (change in) heart rate variability 
and heart rate. Effects were examined by comparing embryos with nonsense mutations in both hcn4 alleles 
and embryos free from CRISPR/Cas9 or sa11188 mutations; as well as using an additive model, weighing the 
number of mutated alleles by their predicted effect on protein function based on Ensembl’s Variant Effect 
Predictor (VEP). Effects were adjusted for time of day and the weighted number of mutated alleles in other 
targeted genes as fixed factors, and with embryos nested in batches and experiment (for the combined analysis, 
random factor). Dots and whiskers represent effect sizes and 95% confidence intervals.
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had a 1.5 to 1.6-fold larger effect on heart rate than on HRV, its protective effect on cardiovascular mortality in 
heart failure patients may indeed be driven by its heart rate lowering  effect28. The larger effect size for heart rate 
than for HRV also suggests that ivabradine may influence HRV at least in part through its non-vagal effects on 
heart rate, supporting an intrinsic effect of heart rate on HRV, as has been postulated  earlier41. Exercise training-
induced bradycardia has previously been shown to result from HCN4  downregulation42. Our findings suggest 
that downregulation of HCN4 may be at least partly responsible for the higher HRV in exercisers, in contrast or 
addition to a higher vagal tone in  exercisers43. With only one affected embryo in the ivabradine experiment, we 
could not examine the role of the drug in prevention of sinoatrial pauses.
Across two separate experiments, we observed that embryos with nonsense mutations in both hcn4 alleles 
have ninefold higher odds of sinoatrial pauses at 5dpf, as well as a higher heart rate and lower HRV in embryos 
free from sinoatrial pauses. Hence, nonselective open  If channel blocking using ivabradine and nonsense muta-
tions in hcn4 have directionally opposite effects on heart rate and HRV in 5dpf zebrafish embryos. Others previ-
ously showed that HCN4+/− humans are typically characterized by  bradycardia44; Hcn4−/− mice die prenatally, 
without arrhythmias and with lower heart rates when compared with Hcn4+/− and Hcn4+/+  mice36; and 2dpf 
zebrafish embryos with experimentally downregulated hcn4 expression have a higher odds of sinoatrial arrests 
and lower heart rate compared with un-injected  controls15. In this light, a higher heart rate in 5dpf zebrafish 
embryos with nonsense mutations in both hcn4 alleles could be considered unexpected. However, results from 
our qRT-PCR experiment suggest that this higher heart rate is likely driven by a compensatory upregulation of the 
expression of HCN1 and HCN2 orthologues. The potential compensatory increase in hcn1 and CABZ01086574.1 
expression is driven by only one sample, but since technical triplicates show coherent results, this may reflect 
the low mutagenic efficiency of the hcn4 gRNA. The likely compensatory increase in hcn2b expression upon 
CRISPR/cas9 targeting of hcn4 was more robust. Results from a Nanopore-OTS screen showed that off-target 
activity of the hcn4 gRNA is highly unlikely to explain our results. Thus, it seems likely that a higher heart rate 
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Figure 6.  qRT-PCR results for the expression of transcripts with high (> 75%) sequence similarity to the 
main zebrafish hcn4 transcript, with and without CRISPR/Cas9 targeting of hcn4, hcn4l, or hcn4 & hcn4l. 
Each sample consists of five pooled, 5-day-old embryos, which at the single cell stage had been injected with: 
(1) hcn4 and hcn4l gRNAs, or Cas9 mRNA (controls, in blue, n = 26); or with Cas9 mRNA together with (2) 
hcn4 gRNA (red, n = 10); (3) hcn4l gRNA (green, n = 12); or (4) hcn4 and hcn4l gRNA (orange, n = 21). In all 
samples, technological triplicates of quantification cycles (Cq) were averaged, and normalized using expression 
in un-injected controls as calibrator, and expression of mob4 as a reference gene, using the Pfaffl method. For 
hcn4 and hcn4l, expression was quantified at the CRISPR/Cas9 targeted site and at the last exon. Differences 
between the three experimental conditions and controls were examined in a multiple linear regression analysis, 
adjusting for batch (n = 2). CABZ01086574.1 is likely an orthologue of the human HCN2. Significant differences 
with controls are highlighted by * (p < 0.05) or # (P < 1 × 10–4). Boxes show mean ± 1 SD. Genes are ordered by 
sequence similarity to the main hcn4 transcript.
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orthologues—serves as an attempt to prevent sinoatrial arrests and sudden cardiac death. This physiological 
attempt to compensate a genetic defect will no doubt be followed by the bradycardia observed in other species 
once the heart can no longer cope with the persistently elevated workload. Besides from an absence of the com-
pensatory response when downregulating gene expression using morpholino  oligonucleotides45, the lower heart 
rate previously reported in 2dpf zebrafish embryos with downregulated hcn415 could also have resulted from 
RNA toxicity, off-target effects, or a developmental delay caused by the microinjection  itself15,46.
Regulator of G protein signaling 6 (RGS6) plays a role in the parasympathetic regulation of heart  rate47 and 
is a negative regulator of muscarinic signaling, thus decreasing HRV to prevent bradycardia. Common variants 
near RGS6 have been identified in GWAS for resting heart  rate6,48,49, heart rate recovery after  exercise49,50 and 
 HRV3. An eQTL analysis using GTEx data showed that the minor T-allele in rs4899412—associated with lower 
HRV—is also associated with a higher expression of RGS6 in whole blood and tibial nerve. This is direction-
ally consistent with humans with loss-of-function variants in RGS6 showing higher  HRV51. Also in line with 
this, Rgs6−/− mice were previously characterized by lower heart rate, higher HRV and higher susceptibility to 
bradycardia and atrioventricular  block52. In our study, zebrafish embryos that were heterozygous for CRISPR/
Cas9-induced mutations in rgs6 on average had a nearly 0.5 SD units lower heart rate at 2dpf. Hence, our results 
for heart rate at 2dpf are in line with studies in mice. The effect on heart rate was no longer apparent at 5dpf, 
in spite of a slightly better statistical power. We did not detect an effect of mutations in rgs6 on HRV or risk of 
sinoatrial pauses or arrests at 2 or 5dpf.
Non-synonymous SNPs in KIAA1755 have been identified in GWAS for  HRV3 and heart  rate5. In our analy-
sis, mutations in si:dkey-65j6.2 tend to result in a higher HRV at 2 and 5dpf, but do not affect heart rate. In 
humans, the minor C-allele of the HRV-associated rs6123471 in the non-coding 3′ UTR of KIAA1755 tends 
to be associated with a lower expression of KIAA1755 in the left ventricle and atrial appendage, amongst other 
tissues  (GTEx53); as well as with a higher  HRV3 and a lower heart  rate4. Hence, a higher HRV at 2 and 5dpf for 
each additional mutated allele in si:dkey-65j6.2 is directionally consistent with results in humans. Our results 
suggest that the GWAS-identified association in the KIAA1755 locus—and possibly other loci—with heart rate 
may have been driven by HRV. This would explain why the eleven HRV-associated loci that showed evidence 
of an association with heart rate all did so in the expected (i.e. opposite) direction from a phenotypic point of 
 view3. KIAA1755 is a previously uncharacterized gene that shows a broad expression pattern, including differ-
ent brain regions and the left atrial appendage  (GTEx53). Future mechanistic studies are required to distill how 
KIAA1755 influences heart rhythm.
In addition to a comparison of specimens with nonsense mutations in both alleles vs. zero mutated alleles, 
we examined the role of mutations in each gene using an additive model. The much larger sample size of this 
alternative approach helped put results from the more traditional approach into perspective. In our pipeline, we 
decided to raise founders to adulthood, and to phenotypically characterize and sequence  F1 embryos, with stable 
genotypes. Screening the  F0 or  F2 generation would have each had their own advantages and disadvantages. Wu 
and colleagues described a powerful approach to efficiently disrupt and analyze  F0  embryos54. However, this 
approach requires drawing conclusions from results in injected, mosaic founders, and is not compatible with 
multiplexing of multiple gRNAs and target sites. Screening the  F2 generation on the other hand requires hand 
picking of  F1 fish with suitable mutations, which limits the throughput.
The large differences in mutant allele frequency across the targeted genes can be attributed to several factors. 
First, mosaic founders were in-crossed six times, using random mating. Hence, different founder fish may have 
produced the screened  F1 offspring in each crossing. Secondly, while all gRNAs were pre-tested for mutagenic 
activity, mutated alleles detected in the test injections that didn’t affect the germline were not included in our 
screen. Thirdly, mutations that are embryonic lethal prior to 2dpf did not make it into the screen.
Of the three genes for which we show effects of mutations on cardiac rhythm and/or rate, only HCN4 is cur-
rently targeted by FDA-approved  drugs55. Although the other two genes are not highlighted as being druggable 
by small molecules, targeting via antisense oligonucleotides, antibodies, or other approaches can be explored. 
Furthermore, expanding our search revealed several druggable interaction partners of putative causal genes that 
are already targeted by FDA-approved anti-hypertensive and neuromuscular blocking agents, amongst others. 
SNAP25, a proposed interaction partner of SYT10, is the target of botulinum toxin A. Injection of botulinum 
toxin A into the neural ganglia of CAD/atrial fibrillation patients was recently shown to reduce the occurrence of 
post-operational atrial  fibrillation56. For existing drugs that target interaction partners of putative causal genes, it 
is worthwhile examining the effect on cardiac rhythm, rate and development, since repurposing FDA-approved 
drugs would imply the quickest and safest route to the clinic. Quantifying possibly unknown beneficial or adverse 
side effects of these drugs related to cardiac rhythm would also be informative.
Four potential limitations of our approach should be discussed. Firstly, acquiring 30 s recordings implies 
that false negatives for sinoatrial pauses or arrests are inevitable. We decided to exclude the embryos with a 
sinoatrial pause or arrest during positioning under the microscope from the analysis, because the case status of 
these embryos cannot be confirmed objectively, but they are not appropriate controls either. This limitation will 
at most have resulted in conservative effect estimates. Secondly, CRISPR/Cas9 gRNAs with predicted off-target 
effects free from mismatches were avoided. However, two of the selected targets—i.e. for hcn4 and si:dkey-
65j6.2—had predicted off-target activity with three mismatches in galnt10 and dclk1, respectively, at the time 
we designed the gRNAs (Supplementary Table S2). Human orthologues of these two genes have previously been 
associated with heart rate variability-related  traits57 (dclk1), as well as with carotid intima-media  thickness58 and 
body mass  index59–61 (galnt10). However, none of the 381 embryos carried CRISPR/Cas9-induced mutations at 
the three predicted off-target sites (Supplementary Table S2). Furthermore, in vitro genome-wide Nano-OTS 
only revealed two off-target sites across the four gRNAs of HCN4 and NEO1 orthologues, both with low muta-
genic activity. Taken together, this implies that gRNA off-target mutagenic activity is extremely unlikely to have 
influenced our results. Thirdly, we in-crossed mosaic founders  (F0) and phenotypically screened and sequenced 
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the  F1 generation. For some genes, this yielded a very small number of embryos with 0 or 2 mutated alleles (i.e. 
for rgs6, hcn4, and hcn4l), resulting in a low statistical power to detect a true role for mutations in these genes. 
In spite of this limitation, we still detected significant effects of mutations in rgs6 and hcn4, and confirmed our 
results for mutations in hcn4 on heart rate and risk of sinoatrial pauses in an independent experiment with 
more statistical power. Unfortunately, the frame rate of image acquisition in the pilot experiment was too low 
to also replicate effects of mutations in hcn4 on HRV. Finally, we recorded the atrium only, to enable a higher 
frame rate, a higher resolution in time for HRV quantification, and a higher statistical power to detect small 
genetic effects on HRV. As a result, any ventricular abnormalities that may have occurred were not registered, 
and uncontrolled atrial contractions may thus reflect atrial fibrillation, premature atrial contractions, high atrial 
rate, or atrial tachycardia.
Strengths of our study include its repeated measures design, which enabled us to capture genetic effects at 
different stages of early development in zebrafish, as well as genetic effects on phenotypic changes over time. 
Furthermore, the throughput of the setup allowed us to examine the effect of mutations in multiple genes simul-
taneously, in a larger than usual sample for in vivo genetic screens. Our results demonstrate that a large sample 
size is paramount to robustly detect genetic effects on complex traits in zebrafish embryos when screening the 
 F1 generation, even for nonsense mutations. Identifying CRISPR/Cas9-induced mutations allele-specifically 
using a custom-written algorithm helped us distinguish between heterozygous and compound heterozygous 
embryos, which in turn helped pinpoint the effect of mutations in these genes. Also, our study is based on a 
high-throughput imaging approach with objective, automated quantification, as compared with manual counting 
and annotation of heart rate in  most4 but not  all12,62 earlier studies. Finally, for all genes that showed an effect on 
HRV, observed effects were directionally consistent with eQTL associations in humans. This further emphasizes 
the strength of our model system and the robustness of our findings.
In conclusion, our large-scale imaging approach shows that zebrafish embryos can be used for rapid and 
comprehensive follow-up of GWAS-prioritized candidate genes for HRV and heart rate. This will likely increase 
our understanding of the underlying biology of cardiac rhythm and rate, and may yield novel drug targets to 
prevent cardiac death.
Methods
Candidate gene selection. Candidate genes in GWAS-identified loci for HRV were identified as described 
in detail in Nolte et al.3. Of the 18 identified candidate genes, six were selected for experimental follow-up. This 
selection was based on overlap with findings from GWAS for heart rate (KIAA1755, SYT10, HCN4, GNG11)4, as 
well as with results from eQTL analyses in sinoatrial node and brain (RGS6). Additional candidate genes from 
the same or nearby loci were also selected for experimental follow-up, i.e. NEO1, which resides next to HCN4. 
Zebrafish orthologues of the human genes were identified using Ensembl, as well as using a comprehensive syn-
teny search using  Genomicus63 (Supplementary Table S1). Of the selected genes, GNG11, SYT10 and RGS6 have 
one orthologue in zebrafish, and HCN4, NEO1 and KIAA1755 each have two orthologues, resulting in a total of 
nine zebrafish orthologues for six human candidate genes (Table 1).
CRISPR/Cas9‑based mutagenesis. All nine zebrafish genes were targeted together using a multiplexed 
CRISPR/Cas9  approach20. Briefly, guide-RNAs (gRNAs) were selected using  ChopChop64 and  CRISPRscan65 
(Supplementary Table S2), based on their predicted efficiency, a moderate to high GC-content, proximal location 
in the protein-coding sequence, and absence of predicted off-target effects without mismatches. Oligonucleo-
tides were designed as  described21, consisting of a T7 or SP6 promoter sequence (for gRNAs starting with ‘GG’ 
or ‘GA’, respectively), a gene-specific gRNA-target sequence, and an overlap sequence to a generic gRNA. The 
gene-specific oligonucleotides were annealed to a generic 80 bp long oligonucleotide at 98 °C for 2 min, 50 °C for 
10 min, and 72 °C for 10 min. The products were checked for correct length on a 2% agarose gel. The oligonucle-
otides were subsequently transcribed in vitro using the manufacturer’s instructions (TranscriptAid T7 high yield 
transcription kit/MEGAscript SP6 transcription kit, both ThermoFisher Scientific, Waltham, USA). The gRNAs 
were purified, after which the integrity of the purified gRNAs was examined on a 2% agarose gel. The zebrafish 
codon-optimized plasmid pT3TS-nls-zCas9-nls was used as a template to produce Cas9  mRNA66. The plasmid 
was linearized with Xba1, and then purified using the Qiaprep Spin Miniprep kit (Qiagen, Hilden, Germany). 
The DNA was transcribed using the mMESSAGE mMACHINE T3 Transcription Kit (ThermoFisher Scientific, 
Waltham, USA), followed by LiCl precipitation. The quality of the RNA was confirmed on a 1% agarose gel.
Husbandry and microinjections. A zebrafish line with GFP-labelled α-smooth muscle cells 
Tg(acta2:GFP)21 was used to visualize the beating heart. To this end, eggs from an in-cross of Tg(acta2:GFP) 
fish were co-injected with a mix of Cas9 mRNA (final concentration 150 ng/μL) and all nine gRNAs (final con-
centration 25 ng/μL each) in a total volume of 2nL, at the single-cell stage. CRISPR/Cas9 injected embryos were 
optically screened for the presence of Tg(acta2:GFP) at 2 days post fertilization (dpf), using an automated fluo-
rescence microscope (EVOS FL Cell imaging system, ThermoFisher Scientific, Waltham, USA). Tg(acta2:GFP) 
carriers were retained and raised to adulthood in systems with circulating, filtered and temperature controlled 
water (Aquaneering, Inc, San Diego, CA). All procedures and husbandry were conducted in accordance with 
Swedish and European regulations, and have been approved by the Uppsala University Ethical Committee for 
Animal Research (C142/13 and C14/16).
Experimental procedure imaging. The mosaic founders  (F0 generation) were only used to yield off-
spring  (F1 embryos) for experiments. To reach the experimental sample size, founders were in-crossed six times 
using random mating. Eggs were collected after founders were allowed to reproduce for 45 min, to minimize 
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variation in developmental stage. Fertilized eggs were placed in an incubator at 28.5 °C. At 1dpf, embryos were 
dechorionated using pronase (Roche Diagnostics, Mannheim, Germany).
At 2dpf, embryos were removed from the incubator and allowed to adapt to controlled room temperature 
(21.5 °C) for 20 min. Individual embryos were exposed to 100 μg/mL Tricaine (MS-222, Sigma-Aldrich, Darm-
stadt, Germany) for 1 min before being aspirated, positioned in the field of view of a fluorescence microscope, 
and oriented dorsally using a Vertebrate Automated Screening Technology (VAST) BioImager (Union Biomet-
rica Inc., Geel, Belgium). We subsequently acquired twelve whole-body images, one image every 30 degrees of 
rotation, using the camera of the VAST BioImager, to quantify body length, dorsal and lateral surface area and 
volume, as well as the presence or absence of cardiac edema. The VAST BioImager then positioned and oriented 
the embryo to visualize the beating atrium and triggered the upright Leica DM6000B fluorescence microscope to 
start imaging using an HCX APO L 40X/0.80W objective and L5 ET, k filter system (Micromedic AB, Stockholm, 
Sweden). Images of the beating atrium were acquired for 30 s at a frame rate of 152 frames/s using a DFC365 FX 
high-speed CCD camera (Micromedic AB, Stockholm, Sweden). After acquisition, the embryos were dispensed 
into a 96-well plate, rinsed from tricaine, and placed back into the incubator. The procedure was repeated at 
5dpf, to allow capturing of genetic effects that influence HRV and heart rate differently at different stages of 
 development22. After imaging at 5dpf, the embryos were once again dispensed into 96-well plates, sacrificed, 
and stored at − 80 °C for further processing.
Quantification of cardiac traits and body size. A custom-written MATLAB script was used to convert 
the images acquired by the CCD camera into quantitative traits. To acquire the heart rate, each frame of the 
sequence was correlated with a template frame. The repeating pattern yields a periodic graph from the cor-
relation values and by detecting the peaks in the graph we can assess the heart rate. The template frame should 
represent one of the extreme states in the cardiac cycle, i.e. end-systole or end-diastole. To detect these frames, 
we examined the correlation between the first 100 frames. The combination of frames that showed the lowest 
correlation corresponded to the heart being in opposite states. One of these frames was chosen as the  template67. 
This numeric information was subsequently used to quantify: (1) heart rate as the inverse of RR-interval; (2) the 
standard deviation of the normal-to-normal RR interval (SDNN); and (3) the root mean square of successive 
heart beat interval differences (RMSSD). Finally, a graph of pixel changes over time was generated across the 
30  s recording to help annotate the script’s performance. Inter-beat-intervals were used to objectively quan-
tify sinoatrial pauses (i.e. the atrium stops contracting for longer than 3 × the median inter-beat-interval of the 
embryo, Fig. 2, Supplementary Recording S1) and sinoatrial arrests (i.e. the atrium stops contracting for longer 
than 2 s, Fig. 2, Supplementary Recording S1). The graphs of pixel changes over time were also used to identify 
embryos with other abnormalities in cardiac rhythm. Such abnormalities were annotated as: uncontrolled atrial 
contractions (Fig. 2, Supplementary Recording S2); abnormal cardiac morphology (i.e. a tube-like atrium, Fig. 2, 
Supplementary Recording S3); or impaired cardiac contractility (i.e. a vibrating rather than a contracting atrium, 
Supplementary Recording S3). These phenotypes were annotated independently by two investigators (BvdH 
and MdH), resulting in an initial concordance rate > 90%. Discrepancies in annotation were discussed and re-
evaluated to reach consensus.
Bright-field images of the embryos were used to assess body length, dorsal and lateral surface area, and body 
volume. Images were automatically segmented and quantified using a custom-written  CellProfiler68 pipeline, 
followed by manual annotation for segmentation quality. Embryos with suboptimal segmentation quality due to 
the presence of an air-bubble on the capillary, a bent body, an incomplete rotation during imaging, partial captur-
ing of the embryo, or an over-estimation of size were replaced by images with a 180° difference in rotation, or 
excluded from the analysis for that outcome if the second image was also sub-optimally segmented. The embryo 
was excluded from the analysis for body volume if more than four of the 12 images had a bad segmentation. 
Imaging, image quantification and image quality control were all performed blinded to the sequencing results.
Quality control of phenotype data. A series of quality control steps was performed to ensure only high-
quality data was included in the genetic association analysis (Supplementary Fig. S2). First, graphs indicating 
that one or more true beats were missed by the script were removed from the analysis a priori (Supplementary 
Fig. S2). Second, embryos showing uncontrolled atrial contractions, sinoatrial pauses or arrests, edema, abnor-
mal morphology and/or reduced contractility, and embryos showing a sinoatrial pause or arrest during position-
ing under the microscope were excluded from the analyses for HRV and heart rate (Supplementary Fig. S2). The 
latter were also excluded from the analysis for sinoatrial pauses and arrests, since we cannot ascertain case status 
for sinoatrial pauses and arrests in the same rigorous manner for such embryos, but they are not appropriate 
controls either. Third, genetic effects were only examined for cardiac outcomes with at least ten cases, i.e. for 
sinoatrial pauses and arrests only.
Sample preparation for sequencing. After imaging at 5dpf, embryos were sacrificed and DNA was 
extracted by exposure to lysis buffer (10 mM Tris–HCl pH8, 50 mM KCl, 1 mM EDTA, 0.3% Tween 20, 0.3% 
Igepal) and proteinase K (Roche Diagnostics, Mannheim, Germany) for 2 h at 55 °C, followed by 10 min at 
95  °C to deactivate the proteinase K. Gene-specific primers (150 bp-300 bp) amplifying gRNA-targeted and 
putative off-target regions in dclk1b and both galnt10 orthologues (Supplementary Table S2) were distilled from 
 ChopChop64 and  Primer369, and Illumina adaptor-sequences were added. Additionally, we included 96 un-
injected Tg(acta2:GFP) embryos for sequencing across all gene-specific regions to not mistake naturally occur-
ring variants for CRISPR/Cas9-induced mutations in our main exposures. The first PCR was conducted by dena-
turation at 98 °C for 30 s; amplification for 35 cycles at 98 °C for 10 s, 62 °C for 30 s and 72 °C for 30 s; followed 
by a final extension at 72 °C for 2 min. Amplified PCR products were cleaned using magnetic beads (Mag-Bind 
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PCR Clean-up Kit, Omega Bio-tek Inc. Norcross, GA). The purified products were used as a template for the 
second PCR, in which Illumina Nextera DNA library sequences were attached to allow multiplexed sequenc-
ing of all CRISPR/Cas9-targeted sites across 383 embryos in a single lane. The second PCR amplification was 
performed by denaturation at 98 °C for 30 s; amplification for 25 cycles at 98 °C for 10 s, 66 °C for 30 s and 72 °C 
for 30 s; followed by a final extension at 72 °C for 2 min. Products were then purified using magnetic beads. All 
liquid handling was performed using a Hamilton Nimbus robot equipped with a 96-head (Hamilton robotics, 
Bonaduz, Switzerland). Samples were pooled and sequenced in a single lane on a MiSeq (2 × 250 bp paired-end, 
Illumina Inc., San Diego, CA) at the National Genomics Infrastructure, Sweden.
Processing of sequencing data. A custom-written bioinformatics pipeline was developed in collabora-
tion with the National Bioinformatics Infrastructure Sweden, to prepare .fastq files for analysis. First, a custom-
written script was used to de-multiplex the .fastq files by gene and well.  PEAR70 was then used to merge paired-
end reads, followed by removal of low-quality reads using  FastX71. The reads were then mapped to the wildtype 
zebrafish genome (Zv11) using STAR 72. Next, we converted files from .sam to .bam format using  samtools73, 
after which variants—mostly indels and SNVs—were called allele specifically using a custom-written variant 
calling algorithm in R (Danio rerio Identification of Variants by Haplotype—DIVaH). A summary of all unique 
sequences identified at each targeted site is shown in Supplementary Fig. S5. All unique variants (Supplementary 
Table S3) located within ± 30bps of the CRISPR/Cas9-targeted sites that were identified across the two alleles 
were subsequently pooled, and used for functional annotation using Ensembl’s  VEP74. Naturally occurring vari-
ants based on sequencing of un-injected Tg(acta2:GFP) embryos or Ensembl were excluded. In absence of a 
continuous score provided by variant effect prediction algorithms, we attributed weights of 0.33, 0.66 and 1 for 
variants with a predicted low, moderate and high impact on protein function. Pilot experiments suggested that 
this was a more powerful approach than not weighing. Transcript-specific dosage scores were then calculated 
by retaining the variant with the highest predicted impact on protein function for each allele, target site, and 
embryo, followed by summing the scores across the two alleles at each target site and embryo. Since all tran-
scripts within a target site were affected virtually identically, we only used the main transcript of each target site 
for the genetic association analysis.
Most embryos had successfully called sequences in all nine CRISPR/Cas9-targeted sites. Embryos with miss-
ing calls at more than two of the nine targeted sites were excluded from the genetic association analysis. For the 
remaining 381 embryos, missing calls were imputed to the mean dosage of the transcript. For neo1b, calling failed 
in 78 embryos (Supplementary Table S4). The imputed mean dosage for the main transcript of neo1b was still 
included in the genetic association analysis, since: (1) the mutant allele frequency in successfully called embryos 
was very high (i.e. 0.934) and an imputed call thus likely closely resembles the truth; and (2) the distribution of 
embryos with a missed call was similar for all outcomes when compared with the remaining embryos. Hence, 
using an imputed dosage was concluded to influence the results less than to either exclude the gene from the 
analysis while it had been targeted; or to discard the 78 embryos that had been successfully phenotyped and 
sequenced for the other targeted genes. However, the results for neo1b should still be interpreted in light of its call 
rate. The mutant allele frequency was low for hcn4, hcn4l and rgs6. No embryos carried CRISPR/Cas9-induced 
mutations within ± 30 bp of any of the three putative off-targets regions (i.e. dclk1b and both galnt10 orthologues, 
Supplementary Table S2).
qPCR to evaluate targeting hcn4 and hcn4l. We performed a qRT-PCR experiment to examine if 
targeting hcn4 and/or hcn4l resulted in a compensatory upregulation of the expression of transcripts with > 75% 
sequence similarity to the main transcript of hcn4. To this end, fertilized eggs of Tg(acta2:GFP) positive fish 
were either: (1) left un-injected; or injected at the single cell stage with: (2) Cas9 mRNA only; (3) hcn4 and hcn4l 
gRNA only; (4) hcn4 gRNA and Cas9 mRNA; (5) hcn4l gRNA and Cas9 mRNA; or (6) hcn4 and hcn4l gRNAs 
and Cas9 mRNA. The same protocols, quantities and gRNAs were used as described above for generating found-
ers (see “Husbandry and microinjections” section). Embryos were raised to 5dpf in an incubator at 28.5 °C. On 
the morning of day 5, within each of the six conditions, multiple pools of five embryos per sample were flash fro-
zen in liquid nitrogen. The experiment was performed twice, with all conditions generated on both occasions, to 
generate a total of 69 samples for conditions 1 to 6 described above. Samples were homogenized in Trizol using a 
20-gauge needle and a 1 mL syringe. RNA was extracted using the TRIzol™ Plus RNA Purification Kit and Phase-
maker™ Tubes Complete System (Cat.No: A33254, Invitrogen, Waltham, MA). The quality and concentration of 
the extracted RNA was measured with the Agilent RNA 6000 nano kit (Cat-No: 5067-1511, Agilent, Santa Clara, 
CA) on an Agilent 2100 Bioanalyzer. In vitro transcription of 100 ng of RNA per sample was performed using 
the SuperScript IN VILO Master Mix (Cat.No: 11755500, Invitrogen), and quantitative PCR was performed in 
triplicate using the PowerUp SYBR Green Master Mix on either an AriaMx (Agilent) or a StepOnePlus (Applied 
Biosystems, Waltham, MA) Real-Time PCR System. Pooled cDNA samples were used to optimize the primer 
concentrations and generate standard curves for the calculation of primer efficiencies. Primers with an efficiency 
close to 100% and a single peak in melt curve analysis were selected (Supplementary Table S11). We used 1 ng of 
cDNA as input for the rest of the reactions with the following cycle conditions: 50 °C for 2 min (1 cycle), 95 °C 
for 2 min (1 cycle), 95 °C for 3 s and 60 °C for 30 s (40 cycles). Differences between the three experimental condi-
tions (conditions 4 to 6) and the two injected controls combined (conditions 2 and 3) on gene expression at the 
hcn4 and hcn4l CRISPR/Cas9-targeted site and at the last exon, as well as for CABZ01086574.1 (HCN2), hcn2b, 
hcn3 and hcn1 (Supplementary Table S11) were examined using Pfaffl’s  method75, taking into account primer 
efficiencies (Supplementary Table S12); expression levels in non-injected controls as calibrator; and expression 
of mob4 as the reference  gene76.
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Nanopore off‑target sequencing (OTS). We next used Nanopore off-target sequencing (Nano-OTS) to 
explore whether CRISPR/Cas9 off-target activity may have influenced the results for hcn4, and whether off-tar-
gets may have caused the relatively large number of missed calls for neo1b. To this end, DNA was extracted using 
the MagAttract HMW kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions for extrac-
tion from tissue. Genomic DNA was fragmented to 20 kb using Megaruptor 2 (Diagenode, Liege, Belgium) and 
size selected with a 10 kb cut-off using the Blue Pippin system (Sage Science, Beverly, MA). Libraries for Nano-
OTS were prepared as described recently by Höijer et al.26. In short, ribonucleoproteins (RNPs) were prepared 
as a pool using the hcn4, hcn4l, neo1a and neo1b gRNAs. Next, 3 µg of fragmented and size-selected DNA was 
dephosphorylated and digested by Cas9 using the RNPs, and DNA ends were dA-tailed. Finally, sequencing 
adapters from the SQK-LSK109 kit (Oxford Nanopore Technologies, Oxford, UK) were ligated to the Cas9-
cleaved ends. Sequencing was performed on one R9.4.1 flow cell using the MinION system (Oxford Nanop-
ore Technologies). Guppy v3.4 was used for base calling. Analysis and calling of OTS sites were performed as 
described by Höijer et al.26, using the GRCz11 reference genome.
Examining druggability of putative causal genes. All human orthologues of the zebrafish genes for 
which we observed (a trend for) an effect were explored in the drug-gene interaction database (DGIdb) v3.0.227. 
Possible interaction partners of the human proteins and genes (Supplementary Table S14) were distilled from 
STRING v10.530 and  GeneMania29, respectively. The GeneMania search was limited to physical interactions and 
pathway data.
Characterizing the effect of treatment with ivabradine. To examine the effect of exposure to ivabra-
dine, the procedures described in “Experimental procedure imaging” section were repeated in embryos free 
from CRISPR/Cas9-induced mutations. On the morning of day 4, embryos were placed in 0, 10 or 25 µM ivabra-
dine in DMSO, for 24 h (Sigma-Aldrich, St Louis, MO). On the morning of day 5, conditions were blinded and 
embryos were imaged as described in the “Experimental procedure imaging” section. Embryos from the three 
blinded conditions were imaged in an alternating manner, to prevent differences in developmental stage from 
influencing the results. The experiment was performed four times to generate a total of 44 embryos per condi-
tion. One embryo with a sinoatrial pause and 13 embryos with suboptimal image or image quantification quality 
were excluded from the analysis, leaving 118 embryos for the analysis of effects on HRV and heart rate.
Statistical analysis. The standard deviation of NN-intervals (SDNN) and the root mean square of suc-
cessive differences (RMSSD) were strongly correlated at 2dpf  (r2 = 0.78) and at 5dpf  (r2 = 0.83), so a composite 
endpoint ‘HRV’ was calculated as the average of SDNN and RMSSD. In embryos free from sinoatrial pauses and 
arrests; abnormal cardiac morphology; impaired cardiac contractility; and edema, we inverse-normally trans-
formed HRV and heart rate at 2dpf (n = 279) and 5dpf (n = 293) to a mean of 0 and a standard deviation of 1, 
so effect sizes and their 95% confidence intervals can be interpreted as z-scores. This approach also ensured a 
normal distribution of all quantitative outcomes, and allowed a comparison of effect sizes across traits. For body 
size analyses, we first normalized dorsal surface area, lateral surface area and volume for body length, and subse-
quently inverse normalized these outcomes as well as body length for the statistical analysis.
Effects of CRISPR/Cas9-induced mutations in candidate genes on sinoatrial pauses and arrests at 2dpf, and 
on sinoatrial pauses at 5dpf were examined using a logistic regression analysis. In embryos free from sinoatrial 
pauses or arrests during the image acquisition, effects of mutations in candidate genes and of ivabradine on 
HRV and heart rate were examined using hierarchical linear models at 2 and 5dpf separately (Stata’s xtmixed), 
adjusted for the time of imaging (fixed factor), and with embryos nested in batches (random factor with fixed 
slope). If a sinoatrial pause or arrest was observed before but not during imaging, embryos were not included 
in the statistical analysis. In a sensitivity analysis, we mutually adjusted associations for HRV and heart rate for 
the other outcome (i.e. for heart rate and HRV) by adding the outcome as an independent variable to the model. 
Effects of CRISPR/Cas9-induced mutations in candidate genes on body size were also examined using hierarchi-
cal linear models, as described above.
For dichotomous outcomes and continuous outcomes alike, genetic effects were examined using an additive 
model, with dosage scores for all nine CRISPR/Cas9 targeted sites as independent exposures in the same model, 
i.e. mutually adjusted for effects of mutations in the other targeted sites. Additionally, for the six genes where at 
least five embryos carried CRISPR/Cas9-induced nonsense mutations in both alleles, these embryos were com-
pared with embryos free from CRISPR/Cas9-induced mutations at that site, adjusting for dosage scores in the 
eight remaining genes. For each outcome, associations were examined for the main transcript of the orthologue.
In the qRT-PCR experiment, the effect of targeting hcn4, hcn4l, or hcn4 & hcn4l on gene expression was 
examined using multiple linear regression analysis, adjusting for batch.
P-values < 0.05 were considered to reflect statistically significant effects. All statistical analyses were performed 
using Stata MP version 14.2 (StataCorp, College Station, TX).
Data availability
Raw data and scripts will be made publicly available after publication if desirable.
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